Mogrify raises $16M for cell therapy

摘要

Biotechnology company Mogrify has raised an additional $16 million to develop its cell therapy programmes.The funding,which brings its total Series A funding to $20 million,will accelerate the company's internal cell therapy programmes and out-licensing of its cell conversion intellectual property.Mogrify CEO Dr Darrin Dislcy said:”We will continue to engage with high-calibre investors with computational biology and cell therapy domain expertise as part of our on-going investor relations and capital markets strategy”